Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Area of Science:

• Biotechnology
• Genetics
• Medical Research

Background:

• Rare diseases present significant global health challenges due to their collective impact and the difficulty in researching treatments.
• Patients with rare diseases often struggle to find expert care and effective therapies.
• Traditional gene therapy development has been slow, taking decades to reach clinical application.

Purpose of the Study:

• To summarize recent achievements in applying CRISPR/Cas technology to rare diseases.
• To outline the remaining hurdles in developing CRISPR/Cas-based therapies for rare conditions.
• To provide an outlook on the future of genome editing for rare disease treatment.

Main Methods:

• Focus on the application of CRISPR/Cas (clustered regularly interspaced short palindromic repeats)/CRISPR-associated protein systems.
• Review of gene therapy advancements, contrasting gene addition with genome editing.
• Analysis of the accelerated timeline from concept to clinical trials for genome editing therapies.

Main Results:

• CRISPR/Cas technology has significantly advanced rare disease therapy development since its eukaryotic application in 2013.
• The development of gene therapies using genome editing, particularly CRISPR/Cas, is now much faster than traditional methods.
• Numerous therapy-development studies for rare diseases have emerged due to CRISPR/Cas refinement.

Conclusions:

• CRISPR/Cas technology represents a paradigm shift in treating rare and orphan diseases.
• The rapid advancement of genome editing tools accelerates the path to clinical trials.
• Despite progress, challenges remain, but the future of rare disease therapy is promising.